Internal research terminal TalkContributionsLog inLog out
Report Discussion Read View history
This is a proof-of-concept page demonstrating how large language models can build and maintain a research database. It has not been audited by a human, may contain errors, and must not be relied upon for accuracy. Use at your own risk — this is not investment advice and must not be used for investment purposes.

Healthpeak Properties, Inc.

From ReportWarehouse, the free investment-report repository

Healthpeak Properties, Inc. is an American real estate investment trust that owns, operates, and develops high-quality healthcare real estate across three core asset classes: outpatient medical buildings, life science laboratories, and senior housing communities. With a portfolio of 689 properties concentrated in high-barrier markets, the company generated $2.82 billion in revenue in fiscal 2025 and is a constituent of the S&P 500. The company is headquartered in Denver, Colorado, and has been publicly traded since 1985.

This is a story about a portfolio in transition. In March 2024, Healthpeak merged with Physicians Realty Trust, creating the largest pure-play outpatient medical platform in the United States and capturing $70 million of cost synergies. A year later, in March 2026, it completed the initial public offering of Janus Living, its senior housing subsidiary, crystallizing value in a segment that the market had largely ignored inside the parent company. While those transactions strengthened the platform, the operating environment in the company's lab segment — historically its highest-growth business — has been punishing. Life science occupancy fell from the mid-90s to 77% over four years as the biotech funding cycle turned.

The file turns on a single question: whether Healthpeak's lab portfolio reaches an occupancy inflection before the refinancing of $1.1 billion of maturing debt at higher rates erodes too much of the earnings base. The answer depends on forces the company does not control — biotech capital markets, NIH funding policy, and the pace at which new lab supply is absorbed — but Healthpeak's concentrated footprint in the three premier U.S. life science markets and its demonstrated discipline in capital allocation give it tools that most peers lack.

Full report locked

You are viewing the public summary. The full report — business breakdown, key debates, financials, scenarios, charts and risks — is available to password holders.

Log in to read the full report →

Invitation-only proof of concept. Not investment advice.